A Randomized, Multicenter, Unblinded, Phase III Study Assessing the Loss of HbsAg at W96 After a 48-week Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (HbeAg Negative) Under Treatment and Responders (Undetectable Viral Load) to a Nucleoside(s) or Nucleotide(s) Analog(s) Treatment for at Least 12 Months. ANRS HB 06 Pegan.

Trial Profile

A Randomized, Multicenter, Unblinded, Phase III Study Assessing the Loss of HbsAg at W96 After a 48-week Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (HbeAg Negative) Under Treatment and Responders (Undetectable Viral Load) to a Nucleoside(s) or Nucleotide(s) Analog(s) Treatment for at Least 12 Months. ANRS HB 06 Pegan.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Nucleosides; Nucleotides
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms PEGAN
  • Most Recent Events

    • 14 Feb 2013 Planned end date changed from 1 Jan 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top